OBJECTIVE:
To present the outcome of a series of 20 patients with JNA with intracranial extension. METHOD: From 1988 to 2010, our multidisciplinary skull base group surgically treated 67 adolescent males with JNA, 20 of this patients presenting intracranial extension. The most frequent symptoms were: nasal obstruction (100%), frequent epitaxis (100%), headaches (80%) and proptosis (35%). All patients presented involvement of the cavernous sinus and spread into the orbit was observed in five. Four patients had been operated before elsewhere. The surgical approach used was the facial degloving associated with microneurosurgery and endoscopy. Preoperative embolization was performed in 20 patients. RESULTS: Total tumor removal was achieved in 17 cases. In this series the intracranial extension was extradural in all cases. In one patient, previously operated in other clinic, the MRI findings suggested intradural tumor. The dura was incised and no intradural tumor was found; CSF leak occurred and the patient developed fungal meningitis that was successfully treated with fluconazole. There was no mortality or permanent morbidity in this series. CONCLUSION: Radical removal of large JNA is difficult due to its extreme vascularization and extension to the orbit, middle and anterior fossa and cavernous sinus. Preoperative embolization, microsurgical and endoscopic techniques are helpful to achieve radical resection with low morbidity.
Local Autoantibodies to Collagen 17A1 in Nasal Polyp Tissue
Robert Kern, MD (presenter); Bruce Tan, MD; Rakesh Chandra, MD OBJECTIVE: Examine nasal polyp tissue for the presence of autoantibodies to collagen 17a -a pathogenic antibody associated with bullous pemphigoid. METHOD: Protein extracts from nasal polyps of 11 patients were compared to inferior turbinate tissue obtained from 10 normal controls using autoantibody microarrays. A positive microarray result for the autoantibodies to the bullous pemphigoid associated antigen anti-BP180 (Collagen XVIIa) was confirmed using 10 nasal polyp samples and 10 normal control samples on commercially available ELISAs for anti-BP180. Immunohistochemistry staining using anti-human Collagen XVIIa was performed to determine its distribution within nasal tissue. RESULTS: Normalized anti-BP180 IgG autoantibodies levels were higher in nasal polyps relative to normal controls on both the antibody microarray (138nfi/mg Total Protein versus 59 nfi/mg Total Protein pϽ0.001) and ELISA (8.7 U/mg Total Protein versus 2.8 U/mg Total Protein pϭ0.03). The elevation of anti-BP180 autoantibodies is localized to nasal polyp tissue. In contrast, inferior turbinate tissue from nasal polyp patients do not demonstrate elevated levels of anti-BP180. Immunohistochemistry staining of normal nasal tissue demonstrates that Collagen XVIIa is localized to the epithelial layer and scattered leukocytes within the lamina propria. CONCLUSION: Anti-BP180 autoantibodies are present at higher levels in nasal polyp tissue than in normal controls: suggesting that a local autoimmune response against an epithelial antigen may be present with nasal polyps. Further studies are needed to test the significance of this autoimmune response to components of the epithelial barrier in the pathogenesis of CRS.
Management of Refractory Rhinosinusitis Caused by MRSA
Mohannad Alqudah, MD (presenter); Mary Ann Jabra-Rizk, PhD; Jeff G Leid, PhD OBJECTIVE: To determine the efficacy of rhinotopic therapy as strategy for treatment of refractory chronic rhinosinusitis (CRS) associated with methicillin-resistant Staphylococcus aureus (MRSA). METHOD: This is a prospective open-label study involving 13 patients with MRSA-related refractory CRS (patients who had persistent symptoms despite endoscopic sinus surgery and prolonged medical therapy). Subjects were treated with rhinotopic therapy consisting of daily nasal nebulization of mometasone and vancomycin or mupirocin (chosen based on nasoendoscopic-guided cultures and sensitivity), daily saline pressure hydrotherapy, weekly endoscopic sinus debridement, and topical intra-sinus installation of a gel that releases the mometasone and same antibiotic, for a period of 6 weeks. Clinical outcome was assessed using the Lund-Kennedy symptom and Lund-Kennedy endoscopic appearance scores. Bacterial elimination was assessed using nasoendoscopic-guided cultures,
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